Telix Pharmaceuticals (TLX) Work In Process (2023 - 2024)

Telix Pharmaceuticals (TLX) reported Work In Process of $9.1 million for Q4 2024, up 133.94% year-over-year from $3.9 million in Q1 2024, and up 133.94% quarter-over-quarter from $3.9 million in Q4 2023.

Telix Pharmaceuticals (TLX) Work In Process (2023 - 2024) Analysis & Trends

Telix Pharmaceuticals (TLX) has 2 years of Work In Process data on file, last reported at $9.1 million in Q4 2024.

  • Work In Process for Q4 2024 came in at $9.1 million, up 133.94% year-over-year; the trailing twelve-month figure through Dec 2024 was $9.1 million (up 133.94% YoY), and the FY2024 annual result was $9.1 million, up 133.94% from the prior year.
  • Work In Process climbed to $9.1 million in Q4 2024 per TLX's latest filing, from $3.9 million in the prior quarter.
  • Over five years, Work In Process peaked at $9.1 million in Q4 2024 and troughed at $3.9 million in Q4 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn -
7 Psyence Biomedical 212.16 Bn 212.16 Bn -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn
9 Abivax 91.96 Bn 91.96 Bn -
10 Telix Pharmaceuticals 4.81 Bn 4.67 Bn -

Historic Data

Download Data
DateValue
Dec 31, 2024 9.08 Mn
Dec 31, 2023 3.88 Mn